Welcome to the UK Toctino^® (alitretinoin) website.

Toctino^® (alitretinoin), distributed by Basilea Pharmaceuticals Ltd., is licensed in the United Kingdom as an oral treatment for patients suffering from severe chronic hand eczema that does not respond to potent topical corticosteroid therapy.

Toctino^® (alitretinoin) is a naturally occurring, physiologic derivative of vitamin A and belongs to the well studied family of retinoids, which are all teratogens; therefore, Toctino^® (alitretinoin) is strictly contraindicated in women of child-bearing potential unless strict pregnancy testing and contraception is followed before, during and one month after cessation of treatment.

The following pages are intended for people who wish to find out more about the Pregnancy Prevention Programme (PPP).

Please also consult the Toctino^® (alitretinoin) Summary of Product Characteristics and the Toctino^® (alitretinoin) Patient Information Leaflet for further details.